Daily Medication Pearl: Natalizumab (Tysarbi)

Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of: multiple sclerosis and Crohn disease.

Medication Pearl of the Day: Natalizumab (Tysarbi)

Indication: Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of multiple sclerosis (MS) and Crohn disease.

Insight:

  • Dosing: 300 mg infused intravenously over 1 hour, every 4 weeks. Do not give as an intravenous push or bolus.
  • Dosage forms: Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial for dilution prior to infusion.
  • Adverse events: Most common adverse reactions (incidence ³ 10%) with natalizumab in MS are headache, fatigue, arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea NOS, and rash.
  • Mechanism of action: Natalizumab binds to the a4-subunit of a4b1 and a4b7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the a4-mediated adhesion of leukocytes to their counter-receptor(s)

Source:

tysabri_prescribing_information.pdf (tysabrihcp.com)